Skye Bioscience, Inc. (SKYE)
USD 3.01
(-7.38%)
USD 3.01
(-7.38%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.61 Million USD | 139.5% |
| 2022 | 1.92 Million USD | -9.78% |
| 2021 | 2.13 Million USD | 42.61% |
| 2020 | 1.49 Million USD | 286.96% |
| 2019 | 387.07 Thousand USD | -71.56% |
| 2018 | 1.36 Million USD | 479.13% |
| 2017 | 235 Thousand USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 47.23 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 5.06 Million USD | 4.82% |
| 2024 Q1 | 4.83 Million USD | 4.78% |
| 2023 FY | 4.61 Million USD | 139.5% |
| 2023 Q4 | 4.61 Million USD | 4.27% |
| 2023 Q2 | 364.65 Thousand USD | 52.01% |
| 2023 Q1 | 239.89 Thousand USD | -87.55% |
| 2023 Q3 | 4.42 Million USD | 1113.85% |
| 2022 Q4 | 1.92 Million USD | -25.5% |
| 2022 Q2 | 2.53 Million USD | 1.93% |
| 2022 Q1 | 2.48 Million USD | 16.37% |
| 2022 FY | 1.92 Million USD | -9.78% |
| 2022 Q3 | 2.58 Million USD | 2.09% |
| 2021 FY | 2.13 Million USD | 42.61% |
| 2021 Q3 | 1.98 Million USD | 18.9% |
| 2021 Q1 | 1.63 Million USD | 9.45% |
| 2021 Q2 | 1.66 Million USD | 1.81% |
| 2021 Q4 | 2.13 Million USD | 7.64% |
| 2020 FY | 1.49 Million USD | 286.96% |
| 2020 Q4 | 1.49 Million USD | 10.43% |
| 2020 Q3 | 1.35 Million USD | 11.35% |
| 2020 Q2 | 1.21 Million USD | 135.27% |
| 2020 Q1 | 517.78 Thousand USD | 33.77% |
| 2019 Q3 | 3.29 Million USD | 6.26% |
| 2019 Q1 | 2.91 Million USD | 114.13% |
| 2019 FY | 387.07 Thousand USD | -71.56% |
| 2019 Q2 | 3.1 Million USD | 6.44% |
| 2019 Q4 | 387.07 Thousand USD | -88.26% |
| 2018 Q4 | 1.36 Million USD | 0.0% |
| 2018 FY | 1.36 Million USD | 479.13% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | -100.0% |
| 2017 Q4 | 235 Thousand USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | 235 Thousand USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q3 | - USD | -100.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | 35.35 Thousand USD | -13.87% |
| 2014 FY | - USD | -100.0% |
| 2014 Q2 | 80.43 Thousand USD | 127.51% |
| 2013 Q2 | 52.52 Thousand USD | -7.85% |
| 2013 Q4 | 41.04 Thousand USD | -13.1% |
| 2013 FY | 47.23 Thousand USD | 0.0% |
| 2013 Q3 | 47.23 Thousand USD | -10.06% |
| 2013 Q1 | 57 Thousand USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 88.799% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -11.968% |
| SQZ Biotechnologies Company | 27.47 Million USD | 83.199% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 89.359% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 84.495% |
| Mesoblast Limited | 118.7 Million USD | 96.112% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -386.703% |
| Genus plc | 233.1 Million USD | 98.02% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -57.497% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -243.504% |
| Marizyme, Inc. | 18.71 Million USD | 75.343% |
| ContraFect Corporation | 2.88 Million USD | -60.197% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -515.369% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -3306.427% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -219.104% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -98.425% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 18.434% |
| MultiCell Technologies, Inc. | 202.58 USD | -2278143.657% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 91.972% |
| EV Biologics, Inc. | 1.49 Million USD | -208.765% |
| Q BioMed Inc. | 4.1 Million USD | -12.294% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 86.057% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -632.492% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -275.726% |
| Biomind Labs Inc. | 735.54 Thousand USD | -527.465% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 97.31% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 64.49% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -419.7% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -3161.257% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 21.39% |
| IMV Inc. | 28.88 Million USD | 84.021% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -17844.967% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -104.362% |
| GB Sciences, Inc. | 1.75 Million USD | -162.334% |
| Alpha Cognition Inc. | 1.22 Million USD | -278.185% |
| HST Global, Inc. | 98.31 Thousand USD | -4594.175% |
| CSL Limited | 12.18 Billion USD | 99.962% |
| Halberd Corporation | 150 Thousand USD | -2976.844% |
| Enzolytics Inc. | 996.33 Thousand USD | -363.223% |
| Resverlogix Corp. | 6.49 Million USD | 28.897% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -866.548% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1705.716% |
| argenx SE | 20 Million USD | 76.924% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 89.87% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -70.387% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -45037.076% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.895% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2200.547% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -92.485% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1912.842% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 93.177% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -52.511% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1183.052% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 77.296% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -3004.704% |
| BioStem Technologies, Inc. | 4.71 Million USD | 2.041% |
| ONE Bio Corp. | 19.71 Million USD | 76.59% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1744.763% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1755.607% |
| Agentix Corp. | 50 Thousand USD | -9130.532% |
| LadRx Corporation | 33.6 Thousand USD | -13633.458% |
| Cell Source, Inc. | 9.25 Million USD | 50.128% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -510.32% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -510.32% |
| NovAccess Global Inc. | 2.19 Million USD | -109.796% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 34.746% |
| Itoco Inc. | 228.37 Thousand USD | -1920.898% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -2087.589% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 7.38% |
| Kadimastem Ltd | 891.22 Thousand USD | -417.856% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1048.508% |
| CytoDyn Inc. | 30.07 Million USD | 84.655% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -853.008% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1211.725% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 40.981% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3667.564% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1388.795% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 2.535% |
| International Stem Cell Corporation | 4.17 Million USD | -10.466% |
| Bioxytran, Inc. | 1.92 Million USD | -139.754% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7294.719% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -111.622% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 44.501% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 46.24% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -196.71% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1622.114% |
| Neutra Corp. | 54.15 Thousand USD | -8422.169% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -152.2% |
| PureTech Health plc | 25.51 Million USD | 81.909% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -276.995% |
| IXICO plc | 472.02 Thousand USD | -877.763% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 70.226% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 92.587% |
| CSL Limited | 12.18 Billion USD | 99.962% |
| Cellectis S.A. | 92.77 Million USD | 95.025% |